miflonide breezhaler
sia novartis baltics - budezonidas - įkvepiamieji milteliai (kietosios kapsulės) - 400 µg; 200 µg - budesonide
oftaquix
santen oy - levofloksacinas - akių lašai (tirpalas) - 5 mg/ml - levofloxacin
penicillin g sodium sandoz
sandoz gmbh - benzilpenicilinas - milteliai injekciniam ar infuziniam tirpalui - 1000000 tv - benzylpenicillin
standacillin
sandoz gmbh - ampicilinas - milteliai injekciniam ar infuziniam tirpalui - 500 mg; 1 g - ampicillin
levofloxacin actavis
teva b.v. - levofloksacinas - akių lašai (tirpalas) - 5 mg/ml - levofloxacin
levofloxacin unimed pharma
unimed pharma spol. s r.o. - levofloksacinas - akių lašai (tirpalas) - 5 mg/ml - levofloxacin
linex
sandoz d.d. - lactobacillus acidophilus (sp. l.gasseri), bifidobacterium infantis, enterococcus faecium - kietosios kapsulės - >=1,2x10(7) ksv; >=1,2x10(7) ksv - lactic acid producing organisms, combinations
arikayce liposomal
insmed netherlands b.v. - amikacin sulfate - kvėpavimo takų infekcijos - antibacterials sisteminio naudojimo, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.